Trial results

$OCGN — OCU400

Ocugen, Inc. (OCGN) OCU400: trial results in Retinitis pigmentosa, 2027.

Research by Catalyst Intel

The catalyst

"1H 2027 topline data expected: 1Q BLA filing target: 2Q"

— Ocugen, 8-K filed 2026-10-15 · the filing. Checked word for word against the stored document when this page was built; a sentence that did not check out would not be here.

Event id

OCGN-OCU400-2026

Company

Ocugen, Inc.

Kind

Trial results

Indication

Retinitis pigmentosa

Window

2027-01-01 – 2027-03-31

Status

slate

The bar

No bar has been published for this event yet.

Verdicts

Sealed with the bar. Any verdict for this event reaches this page on 2027-04-30; subscribers get it on the day.